Karaboué Abdoulaye - french institute of health and medical research

基本信息

浏览量：38

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 75 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Overall Survival According to Time-of-Day of Treatment Administration in 713 Patients Receiving Immunochemotherapy As First Line Treatment Protocol for Advanced Non-Small Cell Lung Cancer: A Bicentric Bicontinental Study

Zhe Huang,Abdoulaye Karaboué,Liang Zeng, Adrien Lecoeuvre, Lemeng Zhang,Xiao-Mei Li,Haoyue Qin, Gabrielle Danino,Feng Yang, Marie-Sara Malin,Li Deng,Marthe Rigal,Hong Liu,Xiang Chen,Qinqin Xu,Lamiae Grimaldi,Thierry Collon,Jing Wang,René Adam,Nong Yang,Boris Duchemann,Yongchang Zhang,Francis Lévi

crossref（2024）

引用0浏览0引用

Neo-wt- RAS in Ctdna: is It Worth Using Anti-EGFR Therapies

Pasquale F Innominato,Abdoulaye Karaboué,Francis A Lévi

JCO precision oncology (2024): e2400628-e2400628

引用0浏览0WOS引用

Why Does Circadian Timing of Administration Matter for Immune Checkpoint Inhibitors’ Efficacy

Abdoulaye Karaboue,Pasquale F. Innominato,Nicholas I. Wreglesworth,Boris Duchemann,Rene Adam,Francis A. Levi

BRITISH JOURNAL OF CANCER (2024)

引用0浏览0WOSNATURE引用

Effect of Immunotherapy-Infusion Time of Day on Survival of Patients with Advanced Cancers: a Study-Level Meta-Analysis

T. Landre,A. Karaboue,Z. S. Buchwald,P. F. Innominato,D. C. Qian,J. B. Assie,C. Chouaid, F. Levi,B. Duchemann

ESMO OPEN（2024）

引用0浏览0WOS引用

Rest-activity Rhythm As a Clinical Biomarker in Cancer

Pasquale F. Innominato,Nicholas Wreglesworth,Abdoulaye Karaboue,David Spiegel,Francis A. Levi

LANCET HEALTHY LONGEVITYno. 7 (2023): E304-E304

引用0浏览0WOS引用

Improved Survival on Morning Pembrolizumab with or Without Chemotherapy During Initial Treatment for Stage IV Non-Small Cell Lung Cancer

Abdoulaye Karaboue,Thierry Collon,Pasquale Innominato,Kader Chouahnia,Rene Adam,Francis Levi

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

Time-dependent Efficacy of Immune Checkpoint Inhibitors in the Treatment of Metastatic Cancers: A Meta-Analysis

Thierry Landre,Abdoulaye Karaboue,Zachary S. Buchwald, Pasquale Innominato David C. Qian,Jean-Baptiste Assie,Christos Chouaid,Francis Levi,Boris Duchemann

Journal of clinical oncologyno. 16_suppl (2023): 2562-2562

引用0浏览0引用

Nivolumab Timing As a Major Survival Predictor in Patients with Stage IV Non–small Cell Lung Cancer

Abdoulaye Karaboue,Thierry Collon,Viviane Bodiguel,Joel Cucherousset,Pasquale Innominato,Mohamed Bouchahda,Rene Adam,Francis Levi

Journal of clinical oncology（2022）

引用0浏览0引用

Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer

Abdoulaye Karaboue,Thierry Collon,Ida Pavese,Viviane Bodiguel,Joel Cucherousset, Elda Zakine,Pasquale F. Innominato,Mohamed Bouchahda,Rene Adam,Francis Levi

Journal of clinical oncology（2022）

引用4浏览0WOS引用

The Future of Precise Cancer Chronotherapeutics

Pasquale F Innominato,Abdoulaye Karaboué, Mohammed Bouchahda,Georg A Bjarnason,Francis A Lévi

The Lancet Oncologyno. 6 (2022): e242

引用2浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn